Clinical Pharmacology-Advances and Applications
Scope & Guideline
Transforming Knowledge into Clinical Applications
Introduction
Aims and Scopes
- Clinical Efficacy and Safety Studies:
The journal emphasizes rigorous clinical trials and studies that evaluate the efficacy and safety of pharmacological agents, including new drug formulations and repurposed medications. - Pharmacokinetics and Pharmacodynamics:
Research exploring the pharmacokinetic properties and pharmacodynamic effects of drugs is a core focus, providing insights into how drugs behave in the body and their therapeutic implications. - Case Reports and Literature Reviews:
The inclusion of detailed case reports and comprehensive literature reviews contributes to the journal's scope, offering valuable real-world insights into clinical practices and outcomes. - Emerging Therapies and Drug Development:
The journal highlights innovative therapies and the development of new drugs, particularly those addressing unmet needs in various disease states, showcasing advances in treatment options. - Natural Products and Drug Repurposing:
Research on the effectiveness of natural products and the concept of drug repurposing, especially in the context of urgent health challenges like infectious diseases, reflects the journal's broad interest in pharmacological advances.
Trending and Emerging
- COVID-19 Therapeutics and Vaccines:
There is a marked increase in research focusing on therapeutics and vaccines related to COVID-19, reflecting the urgent need for effective treatments and preventive measures during the pandemic. - Natural Products in Drug Development:
The exploration of natural products for potential therapeutic use has gained traction, highlighting a resurgence of interest in traditional medicine and its application in modern pharmacotherapy. - Pharmacogenomics and Personalized Medicine:
Emerging studies on pharmacogenomics indicate a growing interest in personalized medicine approaches, tailoring drug therapy based on individual genetic profiles to enhance efficacy and minimize adverse effects. - Innovative Drug Delivery Systems:
Research into novel drug delivery mechanisms, such as mRNA vaccines and other advanced technologies, is trending, showcasing the importance of improving drug administration methods. - Management of Chronic Diseases with New Pharmacological Agents:
There is an increasing focus on the management of chronic diseases, such as diabetes and obesity, with newer pharmacological agents and treatment protocols, reflecting ongoing advancements in therapeutic options.
Declining or Waning
- Traditional Pharmacotherapy Approaches:
There is a declining emphasis on traditional pharmacotherapy methods, as the field moves towards more personalized and targeted therapies, reflecting a broader trend in medicine. - Pharmacotherapy in Rare Diseases:
Research specifically focused on pharmacotherapy for rare diseases appears to be less frequent, possibly due to the increasing complexity and specialization required in these areas. - Over-the-Counter (OTC) Medication Studies:
There has been a reduction in studies focusing on the efficacy and safety of over-the-counter medications, which may indicate a shift towards prescription medications and more complex therapeutic interventions. - Basic Pharmacological Research:
While foundational pharmacology remains important, there seems to be a waning interest in basic pharmacological studies that do not directly translate to clinical applications, as the journal focuses more on immediate clinical relevance. - Pharmacological Education and Training:
Topics related to the education and training of pharmacologists or clinicians have decreased, suggesting a potential gap in addressing the evolving needs of healthcare professionals in the field.
Similar Journals
Ars Pharmaceutica
Championing excellence in pharmaceutical research and innovation.Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.
CLINICAL PHARMACOKINETICS
Unveiling the Future of PharmacotherapyCLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.
PHARMAZIE
Transforming pharmaceutical practices through research.PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.
ANTI-CANCER DRUGS
Advancing the Frontiers of Cancer TherapeuticsANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Exploring the frontiers of clinical and experimental pharmacology.CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
Elevating clinical practice with evidence-based insights.INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.
European Journal of Pharmacology
Unveiling groundbreaking research in pharmacokinetics and toxicology.The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.
ANNALS OF PHARMACOTHERAPY
Fostering Excellence in Medical Research and EducationANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Fostering Knowledge in Pharmacological AdvancementsExpert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Unveiling Insights in Clinical Trials and BeyondBritish Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.